Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- FDA Accepts Re-Filing of Astellas’ Gastric Cancer Med for Review
June 3, 2024
- Lilly Rolls Out Eczema Drug Ebglyss in Japan
June 3, 2024
- Pfizer’s RSV Vaccine Abrysvo Now Available in Japan
June 3, 2024
- Moderna Submits RSV Vaccine in Japan
May 31, 2024
- Nxera Gets US$4.6 Million Milestone over Centessa’s OX2R Agonist
May 31, 2024
- Viatris Launches Cystadrops, Its 1st Brand-Name Product in Japan
May 31, 2024
- Takeda’s cTTP Drug Adzynma Now Available in Japan
May 31, 2024
- Kaken to Transfer Bispecific IP to J&J as US Giant Nabs Asset
May 30, 2024
- AnGes/Vasomune’s ARDS Drug Gets Fast-Track Tag in US
May 30, 2024
- Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
- AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
May 29, 2024
- Boehringer’s Japan Pharma Sales Up 7% in 2023, Buoyed by Ofev, Jardiance
May 29, 2024
- Nippon Shinyaku Chief Defends Benefits of DMD Therapy after PIII Miss
May 29, 2024
- Novel Antibiotic Fetroja Now Available in Taiwan: Shionogi
May 29, 2024
- Cheplapharm to Take Over 2 More Brands from Clinigen in Japan
May 29, 2024
- Fuji Pharma Charts Its Future as Japan’s Leading Biosimilar Player, Stelara Follow-On as Pace Setter
May 28, 2024
- Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
May 28, 2024
- Daiichi Sankyo’s TROP2 ADC Shows OS Benefit in Subgroup of NSCLC
May 28, 2024
- Alzheimer’s Med Leqembi Approved in South Korea, Its 4th Market
May 28, 2024
- Sawai Recalls Antibiotic Cefdinir Manufactured by Choseido, 4 Other APIs
May 27, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…